Correction to: Nationwide Study of Real-World Treatment Patterns and Clinical Outcomes in Patients with Metastatic Urothelial Carcinoma in Hungary
(Source: Advances in Therapy)
Source: Advances in Therapy - December 9, 2023 Category: Drugs & Pharmacology Source Type: research

Oral Treprostinil is Associated with Improved Survival in FREEDOM-EV and its Open-Label Extension
ConclusionInitial treprostinil assignment improved survival in the entire data set; those who began treprostinil after a clinical worsening in the placebo arm and tolerated drug to week  48 enjoyed substantial functional gains.Clinical Trial RegistrationClinicalTrials.gov identifier NCT01560637. (Source: Advances in Therapy)
Source: Advances in Therapy - December 6, 2023 Category: Drugs & Pharmacology Source Type: research

Efficacy and Safety of Disitamab Vedotin Combined with Programmed Death-1 Inhibitor for Advanced Urothelial Cancer: A Case-Series Study
ConclusionsDisitamab vedotin combined with PD-1 inhibitors exhibits a favorable efficacy and safety profile, but subsequent larger cohort clinical studies are required to provide evidence-based medicine for the universal application of this regimen. (Source: Advances in Therapy)
Source: Advances in Therapy - December 4, 2023 Category: Drugs & Pharmacology Source Type: research

The Impact of the COVID-19 Pandemic on Patients with Ulcerative Colitis: Results from a Global Ulcerative Colitis Narrative Patient Survey
ConclusionDuring the pandemic, most patients were satisfied with their current UC treatment plan and access to care; more patients relied on certain alternative UC management support systems, and many were impacted by anxiety/stress.Graphical Abstract (Source: Advances in Therapy)
Source: Advances in Therapy - December 4, 2023 Category: Drugs & Pharmacology Source Type: research

Correction to: Relationship Between Asthma Control Status and Health-Related Quality of Life in Japan: A Cross-Sectional Mixed-Methods Study
(Source: Advances in Therapy)
Source: Advances in Therapy - December 1, 2023 Category: Drugs & Pharmacology Source Type: research

A Linked Electronic Medical Record-Claims Analysis of the Clinical and Economic Outcomes of Patients Coded for Erosive Esophagitis in the United States
ConclusionsPatients with EE are commonly treated with prescription PPIs; however, 19.0% of patients cycled through multiple PPIs. Higher PPI use was associated with a higher comorbidity burden and higher healthcare costs compared to 0  PPI use. (Source: Advances in Therapy)
Source: Advances in Therapy - October 27, 2023 Category: Drugs & Pharmacology Source Type: research

Emotional Journey of Patients with Eosinophilic Esophagitis
ConclusionsThis study pays attention to the different stages of the journey of patients with EoE. There is a lack of awareness by both physicians and patients that negatively affects every stage of the patient journey, but especially the initial phases of pre seeking care and diagnosis. We intend for this article to represent an opportunity to increase EoE awareness and to show the importance of considering the emotional impact on a patient with EoE ’s journey. (Source: Advances in Therapy)
Source: Advances in Therapy - October 27, 2023 Category: Drugs & Pharmacology Source Type: research

Importance of Regular Examination and Follow-up in Pediatric Patients with Neurogenic Bladder: 24-Month Follow-up Study Using a Japanese Health Insurance Database
ConclusionPatients with use of CIC and/or having spina bifida and constipation had a higher risk of UTI, suggesting the need for careful follow-up. More guideline-compliant and diligent patient management is necessary in Japanese children with NGB. (Source: Advances in Therapy)
Source: Advances in Therapy - October 27, 2023 Category: Drugs & Pharmacology Source Type: research

Patient and Caregiver Outcomes After Onasemnogene Abeparvovec Treatment: Findings from the Cure SMA 2021 Membership Survey
ConclusionsThe study suggests that treatment with OA is associated with greater rates of motor milestone achievements and less resource and supportive care use for patients with SMA treated at 6 –23 months of age in the real world. For caregivers, it may also potentially reduce unmet needs, improve HRQOL, and reduce work impairment. (Source: Advances in Therapy)
Source: Advances in Therapy - October 27, 2023 Category: Drugs & Pharmacology Source Type: research

Burden of Disease and Productivity Loss in the European Economic Area in Patients Affected by Fibrosing Interstitial Lung Disease
ConclusionThe impact of non-IPF PPF and SSc-ILD on society is definitely non-negligible. Actions to reduce the burden on our societies are highly needed. (Source: Advances in Therapy)
Source: Advances in Therapy - October 27, 2023 Category: Drugs & Pharmacology Source Type: research

Cardiovascular Insights for the Appropriate Management of Chronic Venous Disease: A Narrative Review of Implications for the Use of Venoactive Drugs
This article summarises a symposium at the XIX World Congress of the International Union of Phlebology held in Istanbul, Turkey, in September 2022. Common pathophysiological features of CVD and cardiovascular disease are endothelial injury, hypercoagulability and systemic inflammation. In CVD, inflammation primarily affects the microcirculation, with changes in capillary permeability, vein wall and valve remodelling and increase in oxidative stress. Once patients develop symptoms/signs of CVD, they tend to reduce their physical activity, which may contribute to increased risk of cardiovascular disease. Data show that the p...
Source: Advances in Therapy - October 27, 2023 Category: Drugs & Pharmacology Source Type: research

Efficacy and Safety of Single-Pill Combination of Rosuvastatin and Ezetimibe in Chinese Patients with Primary Hypercholesterolemia Inadequately Controlled by Statin Treatment (ROZEL): A Randomized, Double-Blind, Double Dummy, Active-Controlled Phase 3 Clinical Trial
ConclusionThe results suggest that SPC R10/E10 improve LDL-C reduction and goal achievement in Chinese patients with primary hypercholesterolemia not adequately controlled on statin therapy, without new safety findings.Trial RegistrationClinicalTrials.gov (NCT04669041). (Source: Advances in Therapy)
Source: Advances in Therapy - October 27, 2023 Category: Drugs & Pharmacology Source Type: research

Nationwide Study of Real-World Treatment Patterns and Clinical Outcomes in Patients with Metastatic Urothelial Carcinoma in Hungary
ConclusionTo our knowledge, this is the first study to assess treatment patterns in patients with mUC in clinical practice in Hungary, using the national health insurance database. Rates of first- and second-line treatment were consistent with those observed in other countries. Avelumab first-line maintenance treatment became available for reimbursement in Hungary in late 2022, after the study period. Given the evolving landscape of reimbursed treatments in Hungary, further analyses are warranted. (Source: Advances in Therapy)
Source: Advances in Therapy - October 27, 2023 Category: Drugs & Pharmacology Source Type: research

Symptom and Treatment Satisfaction in Members of the US and Canadian GBS/CIDP Foundations with a Diagnosis of Chronic Inflammatory Demyelinating Polyneuropathy
ConclusionsA high proportion of members of the US and Canadian GBS/CIDP Foundations reporting a diagnosis of CIDP were unsatisfied with current symptoms, despite a high level of overall satisfaction with treatments. There is an unmet need for improving long-term outcomes in people with a diagnosis of CIDP, and for studying patient-centered long-term treatment goals. (Source: Advances in Therapy)
Source: Advances in Therapy - October 27, 2023 Category: Drugs & Pharmacology Source Type: research

Evaluation of Patient-Reported Outcomes in Patients with Relapsing Multiple Sclerosis Treated with Cladribine Tablets in the CLAWIR Study: 12-Month Interim Analysis
ConclusionThis real-world study demonstrates the effect of cladribine tablets over 12 months on PROs of fatigue, physical function, treatment satisfaction, and work productivity.Trial RegistrationThe CLAWIR study is registered at the German Federal Institute for Drugs and Medical Devices with the internal NIS number 7469. (Source: Advances in Therapy)
Source: Advances in Therapy - October 27, 2023 Category: Drugs & Pharmacology Source Type: research